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ABSTRACT OF THE DISSERTATION 
 
Evaluating rubella epidemiology, vaccine coverage and efficacy, and cost-effectiveness  
to identify strategies for rubella and congenital rubella syndrome elimination  
in the Democratic Republic of Congo 
 
by 
 
Alvan Bing Jun Cheng 
Doctor of Philosophy in Epidemiology 
University of California, Los Angeles, 2020 
Professor Anne W. Rimoin, Chair 
 
Rubella is an acute, usually mild infectious disease characterized by a distinctive red 
rash. One of the major concerns with rubella is when a susceptible pregnant woman contracts 
the disease, and the rubella virus infects the placenta and fetus, leading to a range of birth 
defects known as congenital rubella syndrome (CRS). Despite the availability of a safe and 
effective vaccine, rubella continues to be a leading cause of vaccine-preventable birth defects. 
In the Democratic Republic of Congo (DRC), rubella vaccines are not yet available, and as 
documentation on rubella and CRS has been limited, the burden of infection among adults is 
unknown. The primary concern with introducing rubella vaccination is the potential for an 
increase in CRS incidence as a result of low vaccine coverage, due to the increase in the 
average age of infection. This dissertation aims to provide a backbone for introducing rubella 
vaccination in the DRC by assessing the prevalence and predictors of rubella antibody 
seropositivity, evaluating the impact of vaccination on rubella and CRS burden, and comparing 
the cost-effectiveness of different vaccination scenarios. In the first study, we assess rubella 
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antibody seroprevalence in adults using serology collected through dried blood spots. We found 
that rubella seroprevalence is high among adults in the DRC, and a significant proportion of 
individuals remain susceptible to infection at the beginning of adulthood, including women 
entering reproductive age. The second study investigates the level of disease burden that could 
be reduced by the introduction of rubella vaccination. Rubella transmission dynamics were 
simulated using a stochastic agent-based model, and our results indicate that introduction of 
rubella immunization in the DRC may decrease the burden of rubella and CRS. The third study 
objective was to assess the health and economic impacts of implementing rubella immunization 
under different vaccination scenarios compared to the current no-vaccination scenario in the 
DRC. Cost-effectiveness analyses were conducted on vaccination scenarios by comparing 
incremental net costs per disability-adjusted life-year averted and we found that the introduction 
of rubella vaccination would be highly cost-effective. In conclusion, our results support 
investment in the introduction of rubella vaccination in the DRC. 
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Chapter 1: Introduction and background 
1.1 Rubella infection 
 Rubella is an acute, usually mild disease characterized by a distinctive red rash that 
typically occurs during childhood or early adult life.1 Despite the availability of a safe and 
effective vaccine, rubella continues to be one of the leading causes of vaccine-preventable birth 
defects.2,3 Rubella virus transmission occurs through either direct person-to-person contact or 
through droplet contact from nasopharyngeal secretions; infected individuals are most infectious 
when rash is present, but can shed the virus up to a week prior and after rash onset.4,5 The 
rubella virus is a togavirus of the genus Rubivirus and is an enveloped single-stranded RNA 
virus with a single serotype.6 Humans are the only known reservoir of the rubella virus, and 
once infected, the virus replicates in the nasopharyngeal mucosa and extends to the local lymph 
nodes. After 5 to 7 days following exposure, viremia occurs and results in viral spread to target 
organs.7,8 The rubella virus can then be found in the blood and in respiratory secretions until 
about a week prior to rash onset. Shortly after rash onset, viremia typically disappears, but viral 
shedding in the respiratory tract may persist up to 28 days.7  
The incubation period for rubella is approximately 18 days (range from 12 to 23 days), 
and while symptoms are more common in adults, children tend to show few or no symptoms, 
making rubella infection difficult to detect and diagnose.1 The clinical manifestation of rubella 
infection primarily presents as a rash, which occurs in 50-80% of infected individuals, along with 
other symptoms such as low fever, nausea, runny nose, and conjunctivitis. Starting on the face 
and neck, the rash progresses down the body and lasts between 1 to 3 days.1,9 As rubella 
typically presents as a mild illness, one of the major concerns is when a susceptible pregnant 
woman becomes infected. Infection during pregnancy can result in the rubella virus infecting the 
placenta and fetus, leading to a range of birth defects.7,8 
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1.2 Offspring outcomes 
 Among pregnant women who are infected with rubella during their first trimester, up to 
90% of liveborn infants may have congenital rubella syndrome (CRS), a condition which 
commonly consists of deafness, blindness, mental retardation, and congenital heart defects.1,9,10  
Other issues associated with CRS may include microcephaly, meningoencephalitis, 
hepatosplenomegaly, hepatitis, thrombocytopenia, and radiolucencies in the long bone.1,10 
While some of the defects associated with CRS may be easily diagnosed at birth, many may not 
be detectable until months or years later which may result in lifelong disabilities including 
autism, diabetes, and thyroid dysfunction.9  
Once the fetus is infected, the virus can multiply and damage essentially any organ 
system.7 The degree of organ damage depends highly on the stage of organ maturation with 
earlier infection resulting in more severe damage, thus the rate of CRS declines with gestational 
age.10,11 There are two mechanisms through which organ damage may occur: one through 
mitotic inhibition apoptosis and the other through damage to the vascular endothelium. Damage 
via mitotic inhibition apoptosis may result in the destruction of the ocular lens, retardation of 
growth, bone lesions, and disruption of organ development.12–15 Damage to the vascular 
endothelium may result in encephalitis, mental retardation, and central and cochlear 
deafness.15,16 
 Aside from congenital rubella syndrome, rubella infection during pregnancy may also 
result in miscarriages, stillbirths, therapeutic abortions, and congenital rubella (CRI) without birth 
defects. All congenitally infected infants can shed the rubella virus through pharyngeal 
secretions and through urine up to one year of age, but infants with clinically diagnosed CRS 
have been shown to shed the virus up to 27 months; infants with CRI are still infectious even 
though they present no symptoms.1,8 
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1.3 Detection and diagnosis 
 Detection of rubella cases is heavily reliant on an effective and efficient surveillance 
system and should be conducted in conjunction with measles case-based surveillance due to 
their similar clinical appearances. A rubella surveillance system should include surveillance for 
both rubella cases and CRS cases by targeting newborns and infants up to 11-months old; a 
suspected rubella case is any individual presenting fever, rash, and adenopathy or joint 
paint/inflammation.1,5 Because rubella surveillance is tied with measles surveillance, acquired 
specimens from all suspected cases of measles and rubella should be tested. Typically, 
specimens are tested first for measles-specific immunoglobulin M (IgM), and only those that are 
negative for measles IgM are tested for rubella IgM; testing kits for rubella IgM are more 
expensive, and testing all samples for both measles and rubella is often not a feasible option in 
resource-limited countries.1,10 Detection of rubella-specific immunoglobulin G (IgG) can also be 
used to confirm infection, and in most cases, rubella IgG can be detected 8 days after rash 
onset.1,5,10 A lab-confirmed rubella case is then defined as a suspected rubella case with either 
a positive blood test for rubella IgM, a minimum fourfold increase in rubella IgG, or detection of 
the rubella virus through either reverse-transcriptase polymerase chain reaction (RT-PCR) or 
rubella virus isolation.1,5,10 Regarding CRS, a suspected case would be any infant less than one-
year-old presenting with any combination of heart disease, suspicion of hearing impairment, 
cataract, congenital glaucoma, microphthalmos, or pigmentary retinopathy, as well as any infant 
whose mother has a history of suspected or confirmed rubella infection during pregnancy.1 A 
laboratory confirmed case of CRS is a suspected CRS case who either has a positive blood test 
for rubella IgM, sustained rubella IgG antibody levels, or detection of rubella virus.1,5 
Surveillance for CRS cases should identify the majority of infants with suspected CRS; however, 
there is currently no surveillance system for rubella or congenital rubella syndrome established 
in the Democratic Republic of Congo (DRC). 
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1.4 Burden of disease 
 1.4.1 Worldwide 
 In 2016, there were 22,361 reported cases of rubella from 165 countries, representing a 
97% decline from the 670,894 cases reported in 2000 from 102 countries.2 This decline in the 
number of cases is largely due to the introduction of the rubella-containing vaccine (RCV) into 
the national immunization schedules of 53 additional countries (a total of 152 out of 194 
countries have introduced RCV).2 Only the Region of the Americas has achieved rubella and 
CRS elimination. The European, Western Pacific, and South-East Asia Regions have set control 
and elimination target dates; however, the African Region has yet to set regional rubella goals 
or targets.2,3 As for CRS, it is estimated that more than 100,000 infants are born worldwide with 
CRS annually.4 In the Americas, endemic transmission of rubella and congenital rubella 
syndrome have been eliminated as of 2015 due to the effective use of rubella-containing 
vaccines; the last cases of endemic rubella and CRS in the Americas were reported in 2009.17 
In the European Union, CRS is a rare disease, and since 2002, the number of reported cases 
has varied from 7 to 23 cases annually.18 However, the number of CRS cases remains 
especially high in countries that have yet to introduce RCV into their national immunization 
schedule, such as the Democratic Republic of Congo.19 
 1.4.2 Democratic Republic of Congo 
 In the Democratic Republic of Congo, while documentation on rubella and CRS has 
been limited, the burden of rubella infection is likely to be high. Previous studies have estimated 
that the incidence of CRS in the DRC is approximately 69 per 100,000 live births and that about 
one-third of children and approximately 80% of women of childbearing age are rubella antibody 
seropositive.19,20 Additionally, measles surveillance campaigns have identified rubella cases in 
all provinces within the country.21 Taken together, these results indicate that only is rubella virus 
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prevalent throughout the entire country, but also that a significant proportion of women and 
children remain at risk for rubella infection. In order to effectively reduce the incidence of both 
rubella infection and CRS, rubella vaccination must be implemented through routine 
immunization and achieve high levels of coverage. 
1.5 Research objectives and significance 
 As the Democratic Republic of Congo continues and strengthens its efforts towards 
measles control and elimination, it may present an opportunity and a platform for addressing 
rubella-associated disease burden. Currently, little is known about the epidemiology of rubella 
within the DRC and most of the research done has been focused on children and women, 
primarily women of reproductive age and pregnant women. The first chapter of my dissertation 
aims to expand on the epidemiology of rubella by evaluating the prevalence of rubella 
seropositivity among all adults in the DRC.  
One of the suggested strategies for reducing CRS burden has been to provide 
immunization to only adolescent girls, women of childbearing age, or both.10 However, this 
strategy may not prove effective as rubella transmission would continue among adolescent and 
adult males, and cases of CRS would continue to arise unless all women of reproductive age 
are vaccinated. In several countries where the vaccine campaigns target women of reproductive 
age but not men, large rubella outbreaks continued to occur among males and were followed by 
occurrences of CRS cases.1 Therefore, it is important to understand the epidemiology of rubella 
among adults in the DRC before considering rubella vaccine introduction. Additionally, there 
have been conflicting studies addressing the concern of an increase in CRS burden following 
RCV introduction, as some have found that low RCV coverage may shift the average age of 
infection and result in a spike in CRS cases,22,23 while others have found that this increase may 
not be imminent and that the likelihood of this paradoxical effect is heavily dependent on the R0 
value of rubella.24,25 While measles vaccine coverage in the DRC has yet to reach the 
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recommended 80% threshold for RCV introduction, most countries in the African region 
expected to have an R0 value of rubella between 4-7.26 Thus, the second chapter of my 
dissertation focuses on evaluating the impact of rubella vaccination on rubella and CRS burden 
at the current reported coverage rates for the DRC. If RCV introduction does appear to 
positively impact rubella-associated disease burden in the DRC, it would be important to 
evaluate the related economic consequences by weighing the decrease in disease-associated 
costs against the costs required for vaccine introduction and improved rubella surveillance and 
control. The final chapter of my dissertation therefore examines the cost-effectiveness of 
introducing rubella immunization into the national vaccination schedule of the DRC. Such 
information would benefit decision-makers in making future health policy decisions to ensure 
improved health outcomes while optimizing good value for money. 
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Chapter 2: Rubella Seropositivity Among Adults in the Democratic Republic of Congo 
2.1 Abstract 
Background: Typically a mild disease in children, rubella infection in adults and pregnant 
women can lead to more serious complications as well as miscarriage, fetal death or congenital 
rubella syndrome. Rubella vaccines are not yet available as a part of routine immunization in the 
Democratic Republic of the Congo (DRC), and the burden of infection among adults is 
unknown. 
Methods: In collaboration with the 2013–2014 DRC Demographic and Health Survey, a 
serosurvey was carried out to assess population immunity to vaccine-preventable diseases. Dry 
blood spot samples collected from men 15-59 years of age and women 15-49 years of age were 
processed using the DYNEX Multiplier® chemiluminescent automated immunoassay platform 
(Dynex Technologies, Chantilly, VA). Multivariable logistic regression was then used to 
determine risk factors for rubella seropositivity. 
Results: Among the 15802 adults, 93% were positive for rubella antibody, 6% were negative, 
and 1% were indeterminate for rubella antibodies in weighted analyses. Seroprevalence was 
positively associated with age of respondent and province, with seropositivity highest in Haut-
Katanga (98.37%) and Lualaba (98.04%). In multivariable analyses, serologic evidence of 
infection was associated with age, education level and province. 
Conclusions: Rubella seroprevalence is high among adults in the DRC, and although most 
viremia and antibody seroconversion occur before 15 years of age, over 10% of individuals 
remain susceptible to rubella infection at the beginning of adulthood, including women entering 
reproductive age. To reduce the risk of rubella and CRS, rubella vaccination must be introduced 
into the national immunization schedule and achieve high coverage. Evaluating the economic 
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impact and costs associated with vaccine introduction will play an important role in identifying 
effective immunization strategies and informing future policy decisions. 
2.2 Introduction 
 Rubella is a vaccine-preventable disease that is spread through either direct 
person-to-person contact or through droplet transmission via nasopharyngeal secretions.1,2 
Despite the availability of a safe and effective vaccine, rubella infection continues to be one of 
the leading causes of vaccine-preventable birth defects.3 Among those infected, up to 50% may 
be asymptomatic or subclinical; individuals that are symptomatic commonly present with rash 
and low-grade fever, along with any combination of nausea, malaise, mild conjunctivitis, upper 
respiratory infection, and lymphadenopathy.4–6 Symptoms tend to be mild and resolve within 1-5 
days; however, symptoms in older children and adults may be more severe, such as joint pain 
and encephalitis.7–9 Additionally, rubella infection in a pregnant woman may result in 
miscarriage, stillbirth, or congenital defects known as congenital rubella syndrome (CRS).10,11 
The defects associated with CRS commonly include blindness, deafness, mental retardation, 
and congenital heart disease.12–14 Up to 90% of pregnant women infected during the first 
trimester may give birth to an infant with CRS, and the risk declines with gestational age.15 
Since the introduction of rubella-containing vaccines (RCVs) in 1969, the incidence of 
rubella and CRS cases has decreased significantly, and the mortality and morbidity associated 
with rubella infection has become completely preventable.16,17 From 2000-2016, global RCV 
coverage increased by 26%, which has resulted in a 97% decrease in the number of reported 
cases of rubella.17 Only the Region of the Americas has achieved rubella and CRS elimination, 
and in order to achieve the 2020 rubella elimination goals set by the Global Vaccine Action Plan 
2011-2020, RCV introduction must continue and maintain high coverage rates.18 The African 
Region has yet to set regional rubella goals or targets for elimination, and in countries where 
RCV has yet to be introduced into the national immunization schedule, the burden of rubella and 
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CRS is likely to be high. Estimates from 2010 have suggested that the incidence of CRS in 
Africa alone was 116 per 100,000 live births, corresponding to approximately 38,000 cases.19  
In the Democratic Republic of the Congo (DRC), rubella vaccination is currently not part 
of the routine immunization (RI) schedule, and there is no specific surveillance system for 
detecting rubella and CRS cases. However, the country does have a measles-case based 
surveillance (CBS) system which tests for rubella IgM on specimens that are negative or 
indeterminate for measles IgM. Despite limitations in documentation, recent studies have 
estimated the incidence of CRS to be 69 per 100,000 live births and that approximately one-
third of children 6- to 59-months are rubella antibody seropositive.20,21 Additionally, a study 
analyzing data collected between 2004-2013 from the measles CBS system found that about a 
quarter of the samples tested for rubella IgM were positive and that the percentage of cases 
positive for rubella IgM through this system had increased from 20% in 2005 to 46% in 2013.22 
Taken together, these results indicate that not only is the number of identified rubella cases 
increasing, but also that rubella virus is circulating in the DRC and that a significant proportion of 
the population remains susceptible to rubella infection.  
However, since only specimens from individuals presenting measles-like symptoms are 
collected, and only a subset of these are tested for rubella IgM, the true burden of rubella 
among adults in the DRC is unknown. Therefore, using the 2013-2014 Demographic and Health 
Survey (DHS), we assessed the prevalence of rubella antibody seropositivity in individuals 15-
59 years of age in order to provide nationally representative estimates of rubella infection 
among adults in the DRC. 
2.3 Methods 
 The DRC is a developing country split into 26 provinces with an estimated population of 
78.7 million inhabitants.23 The second DHS (EDS-RDC II) conducted in the DRC took place 
from November 2013 to February 2014 using a 2-staged stratified cluster design.24 These 
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surveys are designed to be nationally representative and to collect data on maternal and child 
health, as well as basic demographic and health information.25 Information on sampling design 
and data collection procedures are described in more detail elsewhere.26 Data were collected 
from a nationally representative sample of 18,171 households in which only women 15-49 years 
of age and men 15-59 years of age were eligible to participate in the survey. Data collected 
include, but are not limited to, demographics, health outcomes, and household composition. 
 In addition to survey data, dried blood spots (DBS) were collected from all consenting 
adults in households where men were approached for individual questionnaires (approximately 
50% of households) and analyzed for biomarker data to assess population immunity to vaccine-
preventable diseases (VPDs). All survey data from the paper questionnaires were converted to 
an electronic format using the Census and Survey Processing System (US Census Bureau, ICF 
Macro, Rockville, MD). All questionnaires are double entered and checked for inconsistencies 
by comparing the two datasets.  
 DBS samples were collected using a modified extraction protocol and analyzed at the 
UCLA-DRC laboratory in collaboration with the Kinshasa School of Public Health located at the 
National Laboratory for Biomedical Research in Kinshasa, DRC.27 Laboratory testing was 
completed using a prototype DYNEX Multiplier® chemiluminescent automated immunoassay 
instrument with a Measles, Mumps, Rubella, Varicella, and Tetanus (MMRVT) multiplex plate. 
Quarter inch DBS samples were eluted out in phosphate buffered saline containing 0.05% 
Tween-20 and 5% dried milk, equating to a 1:143-fold dilution assuming 7 μl of serum per DBS 
sample. Polystyrene beads coated separately with antigen to measles, mumps, rubella, 
varicella-zoster virus, and tetanus were immobilized within 54-well M² assay strips with 10 
beads per well and processed for IgG antibody detection. Based on epidemiologic studies, the 
positive/negative cutoff for rubella IgG antibody detection used in our analyses was set at an 
Assay Score (AS) of 0.37.28,29 
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 To assess predictors of rubella seropositivity among adults, χ2 analyses were conducted 
on the weighted samples to assess sociodemographic differences between positive and 
negative test results. Independent predictors of seropositivity were identified through univariate 
logistic regression models. Multivariable logistic regression models were run with all variables 
and then with only significant predictors based on backwards selection using Akaike information 
criterion (AIC) and Bayesian information criterion (BIC). Of the 8,206 individuals with serology 
data, 7,914 were successfully matched to the DHS dataset. Adults with missing (n=48) or 
indeterminate serologic test results (n=96) were excluded from the analyses, but those with 
indeterminate values were included in sensitivity analyses to assess the impact of their removal 
on the results. Maps of rubella seropositivity prevalence by province were created to examine 
the spatial distribution of serologic response in adults. All analyses were conducted using SAS 
software, version 9.4 (SAS Institute, Cary, NC), and maps were created using ArcGIS software 
version 10.6 (ESRI, Redlands, CA). 
Ethical approval for this study was reviewed and approved by the Ethics Committee of 
the Kinshasa School of Public Health, Kinshasa, DRC, and by the Institutional Review Board of 
Human Research Ethics at the University of California, Los Angeles. Informed consent was 
obtained from all enrolled participants as a part of the DHS survey. 
2.4 Results 
 Among the 7,866 adults included in the analyses, 7,234 (92%) were positive for rubella 
antibody, 536 (7%) were negative, and 96 (<1%) were indeterminate. After applying the DHS 
sampling weights, the total sample size resulted in 15,802 adults in which 14,610 (93%) were 
positive, 998 (6%) were negative, and 194 (1%) were indeterminate. 
 Overall, the prevalence of rubella antibody among adults was high in all provinces (Fig. 
1). The provinces with the highest prevalence were Haut-Katanga (98.37%) and Lualaba 
(98.04%); Bas-Uele had the lowest (87.25%). Adults who were older (>24 years of age), had 
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higher education, or had higher socioeconomic status were more likely to test positive for 
rubella IgG antibody relative to their younger, less educated, and lower socioeconomic status 
counterparts (Table 1). Controlling for age, the positive relationship between education level and 
seropositivity remained in all age groups (Fig. 2). Analysis of the serologic test results revealed 
a positive linear relationship between age and seropositivity; rubella seropositivity increased 
from 89.5% of 15-year-olds to 100% of 59-year-olds (Fig. 3).  
Overall, those living in urban areas were more likely to be seropositive than rural 
residents (Table 1). Within provinces, this association only held for Kinshasa, Kasai-Oriental, 
and Haut-Katanga; for the remaining provinces, rubella seropositivity was more likely to be 
found in rural areas than urban ones (Fig. 4). Additionally, those living in areas of higher 
population density were also more likely to be seropositive compared to those living in lower 
population density areas (Table 1).  
 In multivariable analyses, the odds of rubella seropositivity increased with increasing age 
up to age 45 (the odds of a positive test result for rubella antibodies was 3.52 times higher for 
adults aged 40-44 compared to 15-19 year olds; adults aged 45+ had 1.99 times the odds of a 
positive serologic test compared to 15-19 year olds), level of education (no education compared 
to secondary or higher education), and province (Haut-Katanga and Lualaba had the highest 
odds of rubella seropositivity, and Sankuru had the lowest compared to Kinshasa; Table 2). 
Inclusion of those with indeterminate serology did not impact our results (data not shown). 
2.5 Discussion 
 The results of our study reveal that rubella virus may be widely circulating throughout the 
DRC: among adults 15-59 years of age, the prevalence of rubella-specific IgG antibodies was 
>87% in all provinces. These results are consistent with other studies that have examined 
rubella seroprevalence in other countries of the African region in the pre-vaccine era.30 In a 
meta-analysis of three studies of rubella seropositivity among women of reproductive age, 
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rubella seropositivity was found to be 94.1% in women 14-18 years of age in Ethiopia, 90.1% in 
women 15-45 years of age in Senegal, and 84% in women 15-34 years of age in Côte d’Ivoire.30 
While these studies included only women, they found that rubella virus was circulating widely in 
Africa and that rubella infection during pregnancy occurred throughout the region prior to RCV 
introduction.  
Rubella seropositivity was found to be associated with both age and province: 91% of 
adults aged 15-19 and 95% of adults aged 45+ tested positive for rubella antibody, with the 
highest prevalence in Haut-Katanga and Lualaba provinces. Our finding of a positive 
relationship between age and rubella seropositivity is consistent with previous findings from 
studies assessing rubella immunity in other African countries.31,32 A study conducted in Ethiopia 
found that, prior to rubella vaccine introduction, 66.7% of pregnant women 16-19 years of age, 
79.9% of pregnant women 25-34 years of age, and 82.3% of pregnant women 35-40 years of 
age tested positive for rubella-specific IgG antibodies.31 In a study of pregnant women in 
Namibia, the prevalence of rubella seropositivity increased from 83% of 15-19 year olds to 90% 
of 40-44 year olds.32 However, these studies are limited only to pregnant women, and the 
results are likely not representative of adults, or even women, in these regions. 
As DRC currently relies on its measles CBS to identify cases of rubella infection and 
rubella is not a reportable disease, it is likely that the estimates obtained through this system are 
an underestimation and not representative of the true burden of infection. Among the rubella 
cases identified through this system, only 5% were among those 15 years of age or older (60% 
of which were female).22 In our study, we found that among 15-year-olds, 89% of both males 
and females had serologic evidence of rubella infection and that seropositivity increased with 
age for both genders. These results indicate that, although most viremia and antibody 
seroconversion occur before 15 years of age, over 10% of individuals remain susceptible to 
rubella infection at the beginning of adulthood, including women entering reproductive age. This 
is concerning as rubella infection during pregnancy may lead to a range of adverse outcomes, 
16 
including miscarriage, stillbirths, and infants born with either CRS or congenital rubella infection 
(CRI).1,15,33,34 An estimated 90% of fetuses are affected by multiple defects when rubella 
infection occurs just before conception or during the first trimester.15 The risk of congenital 
defects decreases with gestational age, and maternal rubella infection after the 16th week of 
pregnancy are rarely associated with fetal defects.34 In order to reduce the risk of rubella and 
CRS, rubella vaccination must be introduced into the national immunization schedule and 
achieve high coverage. 
This study has a number of limitations. We presumed that a positive test result for 
rubella IgG was the result of natural infection; however, some adults may have had the 
opportunity to receive vaccination – while unlikely. As DHS does not collect any data on 
vaccines provided outside of the national government for pregnant women and children under 5 
years old, we were unable to verify whether any individuals received immunization against 
rubella. Additionally, there might be misclassification of serostatus due to the testing method. 
However, compared to four commercially available kits, the DYNEX Multiplier® assay exhibited 
high validity for both sensitivity (range: 89.5–100%) and specificity (range: 77.3–100%); 
therefore, it is unlikely that misclassification would significantly impact our findings.29 
Furthermore, the cost-effectiveness of the multiplex assay outweighed this limitation as we were 
also able to evaluate the serology of four other vaccine-preventable diseases. Due to the 
presence of serologically indeterminate results, we initially excluded these adults from our 
analyses, yet in sensitivity analysis, inclusion of these individuals did not change our results. 
Our data suggest that although rubella virus is circulating among adults throughout the DRC, a 
significant proportion of adults remain susceptible to infection at the start of adulthood and 
throughout reproductive age.  
There exists a safe and effective rubella vaccine, yet only a small number of sub-
Saharan African countries have introduced it into their national immunization schedule.35 
According to the WHO, countries should have well-established and effective immunization 
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programs capable of achieving high levels (≥80%) of measles vaccination coverage through RI 
and supplementary immunization activities (SIAs) before introducing RCV to avoid potentially 
increasing the risk of CRS.16,36 In the DRC, national estimates from WHO-UNICEF reveal that 
measles RI coverage reached 80% in both 2017 and 2018.37 Provided with adequate funding, 
resources, and political will, the rubella antigen may be easily integrated into the RI schedule. 
This is one of the few studies to provide nationally representative estimates of rubella 
infection among adults in the DRC and may help to inform policy decisions and to identify 
effective vaccination strategies.10,38 Currently, there are tentative plans for RCV introduction into 
the national immunization schedule before 2020, with goals of organizing catch-up SIAs for 
rubella and establishing a system for monitoring CRS.39 In the interim, it is important to both 
understand the impact of vaccination at lower than recommended coverage levels, especially on 
the incidence of CRS, and to evaluate the economic impact and costs associated with vaccine 
introduction. In the meantime, the country should focus on strengthening surveillance efforts 
and following the Global Measles and Rubella Strategic Plan, specifically achieving and 
maintaining high levels of population immunity and conducting research and development in 
support of cost-effective operations.3 Monitoring disease progress and improving the capacity to 
maintain nationally high vaccine coverage levels will be crucial next steps in advancing toward 
rubella and CRS elimination.   
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2.6 Tables and figures 
Table 2.1. Weighted Demographic Characteristics of 2013-2014 DRC-DHS Respondents 15-59 
Years of Age by Rubella Serosurvey Results 
 
Negative  
(n = 998) 
Positive  
(n = 14610)  
 
n % n % 
χ2  
P-Value 
Respondent's information           
Age     <.0001 
15-19 yrs* 302 30.3 2935 20.1  
20-24 yrs 217 21.8 2619 17.9  
25-29 yrs 162 16.2 2444 16.7  
30-34 yrs 121 12.1 1875 12.8  
35-39 yrs 56 5.6 1599 10.9  
40-44 yrs 39 3.9 1310 9.0  
45+ yrs 99 10.0 1827 12.5  
Sex  
 
 
 
0.5746 
Male 487 48.8 6828 46.7  
Female 511 51.2 7782 53.3  
Number of household members  
 
 
 
0.7277 
1-3 159 15.9 2047 14.0  
4-6 372 37.3 5465 37.4  
5-9 287 28.8 4554 31.2  
10+ 180 18.0 2544 17.4  
Highest level of education  
 
 
 
0.9244 
No education 105 10.5 1523 10.4  
Primary 320 32.1 4523 31.0  
Secondary/higher 573 57.4 8543 58.6  
Wealth index†  
 
 
 
0.3296 
Poorest 211 21.2 2657 18.2  
Poorer 213 21.3 2886 19.8  
Middle 203 20.3 3064 21.0  
Richer 196 19.6 2703 18.5  
Richest 175 17.6 3299 22.6  
Province  
 
 
 
0.0032 
Kinshasa 78 7.8 1627 11.1  
Kwango 34 3.4 708 4.8  
Kwilu 80 8.1 944 6.5  
Mai-Ndombe 44 4.4 680 4.7  
Kongo Central 54 5.5 558 3.8  
Equateur 33 3.3 446 3.1  
Mongala 34 3.4 385 2.6  
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Nord-Ubangi 22 2.2 236 1.6  
Sud-Ubangi 42 4.2 706 4.8  
Tshuapa 19 1.9 351 2.4  
Kasai 38 3.8 410 2.8  
Kasai-Central 51 5.1 590 4.0  
Kasai-Oriental 45 4.5 588 4.0  
Lomami 69 7.0 640 4.4  
Sankuru 36 3.6 231 1.6  
Haut-Katanga 4 0.4 641 4.4  
Haut-Lomami 10 1.0 358 2.4  
Lualaba 2 0.2 298 2.0  
Tanganyka 28 2.8 246 1.7  
Maniema 41 4.1 450 3.1  
Nord-Kivu 78 7.8 1208 8.3  
Bas-Uele 29 2.9 293 2.0  
Haut-Uele 32 3.3 268 1.8  
Ituri 24 2.4 464 3.2  
Tshopo 37 3.7 436 3.0  
Sud-Kivu 32 3.2 849 5.8  
Population density‡  
 
 
 
0.7138 
Low 513 51.5 7076 48.4  
Medium 229 23.0 3553 24.3  
High 255 25.6 3981 27.2  
Residence  
 
 
 
0.0783 
Urban 312 31.3 5402 37.0  
Rural 685 68.7 9208 63.0  
     *Only women between the ages of 15-49 and men between the ages of 15-59 were invited to 
participate in the survey. 
     †Wealth index is an aggregate measure of the household's cumulative living standard taking account of 
the household's ownership of selected assets, materials used for housing construction, and types of water 
access and sanitation facilities. 
     ‡Population density was calculated by dividing the population of each province (based on projections 
from the latest census) by the area of each province (in km2) and then categorizing into tertiles. 
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Table 2.2. Weighted Logistic Regression of Sociodemographic Factors Associated with Rubella 
Seropositivity of 15 to 59-Year-Old 2013–2014 DHS Respondents 
 ORcrude (95% CI) ORadjusted
*
 (95% CI) 
Respondent's information     
Age   
15-19† ref ref 
20-24 1.24 (0.92-1.68) 1.26 (0.92-1.72) 
25-29 1.56 (1.06-2.29) 1.63 (1.10-2.42) 
30-34 1.60 (1.06-2.41) 1.67 (1.09-2.54) 
35-39 2.94 (1.78-4.84) 3.13 (1.89-5.17) 
40-44 3.45 (1.63-7.30) 3.52 (1.65-7.49) 
45+ 1.89 (1.13-3.16) 1.99 (1.17-3.38) 
Sex   
Male ref - 
Female 1.09 (0.81-1.45) - 
Number of household members   
1-3 ref - 
4-6 1.14 (0.82-1.58) - 
5-9 1.23 (0.87-1.73) - 
10+ 1.10 (0.73-1.64) - 
Highest level of education   
No education 0.98 (0.68-1.41) 0.79 (0.54-1.15) 
Primary 0.95 (0.70-1.28) 0.91 (0.67-1.24) 
Secondary/higher ref ref 
Wealth index‡   
Poorest ref - 
Poorer 1.20 (0.87-1.66) - 
Middle 1.08 (0.73-1.59) - 
Richer 1.10 (0.74-1.63) - 
Richest 1.50 (1.01-2.21) - 
Province   
Kinshasa ref ref 
Kwango 0.99 (0.41-2.36) 0.99 (0.42-2.37) 
Kwilu 0.56 (0.24-1.29) 0.57 (0.24-1.33) 
Mai-Ndombe 0.74 (0.30-1.82) 0.76 (0.30-1.89) 
Kongo Central 0.49 (0.23-1.03) 0.51 (0.25-1.06) 
Equateur 0.65 (0.35-1.19) 0.65 (0.34-1.26) 
Mongala 0.54 (0.29-0.99) 0.56 (0.30-1.04) 
Nord-Ubangi 0.50 (0.23-1.10) 0.52 (0.23-1.19) 
Sud-Ubangi 0.80 (0.41-1.57) 0.87 (0.45-1.69) 
Tshuapa 0.88 (0.38-2.02) 0.91 (0.39-2.12) 
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Kasai 0.51 (0.24-1.08) 0.56 (0.28-1.12) 
Kasai-Central 0.56 (0.27-1.17) 0.58 (0.27-1.25) 
Kasai-Oriental 0.62 (0.32-1.22) 0.66 (0.34-1.31) 
Lomami 0.44 (0.25-0.78) 0.48 (0.27-0.84) 
Sankuru 0.31 (0.17-0.57) 0.32 (0.17-0.60) 
Haut-Katanga 7.93 (2.48-25.38) 8.54 (2.66-27.43) 
Haut-Lomami 1.70 (0.62-4.65) 1.85 (0.66-5.17) 
Lualaba 5.82 (1.33-25.44) 6.26 (1.41-27.84) 
Tanganyka 0.42 (0.20-0.86) 0.45 (0.22-0.94) 
Maniema 0.52 (0.21-1.31) 0.52 (0.21-1.32) 
Nord-Kivu 0.74 (0.36-1.53) 0.813(0.38-1.78) 
Bas-Uele 0.48 (0.19-1.23) 0.49 (0.19-1.29) 
Haut-Uele 0.39 (0.17-0.90) 0.41 (0.18-0.94) 
Ituri 0.93 (0.34-2.53) 1.03 (0.36-2.90) 
Tshopo 0.57 (0.29-1.11) 0.58 (0.29-1.17) 
Sud-Kivu 1.25 (0.58-2.71) 1.35 (0.61-2.97) 
Population density¥   
Low ref - 
Medium 1.13 (0.77-1.64) - 
High 1.13 (0.82-1.57) - 
Residence   
Urban 1.29 (0.97-1.71) - 
Rural ref - 
     *Using backwards selection, only significant predictors (based on Akaike information criterion and Bayesian 
information criterion) were retained in the final model; predictors in adjusted model include respondent's age, highest 
level of education, and province. 
     †Only women between the ages of 15-49 and men between the ages of 15-59 were invited to participate in the 
survey. 
     ‡Wealth index is an aggregate measure of the household's cumulative living standard taking account of the 
household's ownership of selected assets, materials used for housing construction, and types of water access and 
sanitation facilities. 
     ¥Population density was calculated by dividing the population of each province (based on projections from the 
latest census) by the area of each province (in km2) and then categorizing into tertiles. 
     OR indicates odds ratio; CI, confidence interval. 
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Figure 2.1. Geographic distribution of rubella seropositivity for 2013-2014 DRC-DHS by 
province among women 15-49 years of age and men 15-59 years of age. 
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Figure 2.2. Percent of positive rubella antibody test results according to education level within 
age groups among 15- to 49-year-old female and 15- to 59-year-old male 2013-2014 DRC-DHS 
respondents. 
 
Figure 2.3. Percent of rubella seropositivity by age and sex among 15- to 49-year-old female 
and 15- to 59-year-old male 2013-2014 DRC-DHS respondents (with linear trend lines). 
0
20
40
60
80
100
15-19 20-24 25-29 30-34 35-39 40-44 45+
%
Age (years)
Secondary/higher
Primary
No education
84
86
88
90
92
94
96
98
100
15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59
%
Age in years
Male
Female
Linear (Male)
Linear (Female)
Education level 
24 
 
Figure 2.4. Rubella seroprevalence according to place of residence for 2013-2014 DRC-DHS 
by province among women 15-49 years of age and men 15-59 years of age. 
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Chapter 3: Modeling the Impact of Rubella Immunization in the Democratic Republic of 
Congo 
3.1 Abstract 
Background: Rubella infection among adults can result in severe complications, especially 
among pregnant women which may lead to infant mortality or infants born with congenital 
defects. In the Democratic Republic of Congo, rubella and congenital rubella incidence is high, 
but measles eradication efforts may provide an opportunity for potential interventions. This 
paper investigates the level of disease burden that could be reduced by incorporating rubella 
vaccination into the national immunization schedule as a combined measles-rubella-containing 
vaccine. 
Methods: We modeled two vaccination scenarios using an agent-based disease transmission 
model to simulate natural rubella dynamics along with the effect of immunization. We compared 
estimates of rubella infection and congenital rubella syndrome burden over a 30-year period 
against modeled estimates resulting from the current scenario of no vaccination. Levels of 
routine immunization were assigned at the province level. 
Results: With no rubella immunization, our model estimated there to be 151,021,183 rubella 
cases and 147,543 congenital rubella syndrome cases. After introducing rubella vaccine, the 
number of rubella cases decreased to 1.5-8.1 million cases and congenital rubella syndrome 
cases decreased to 2.9-27.1 thousand cases depending on the vaccination scenario. 
Conclusions: The likelihood of an increase in congenital rubella syndrome burden as a result of 
low vaccine coverage heavily depends on the basic reproduction number of rubella. Modeling 
results indicate that introduction of rubella immunization in the Democratic Republic of Congo at 
the current reported vaccination rates may decrease the burden of rubella and congenital 
rubella syndrome. 
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3.2 Introduction 
The rubella virus (RV), a togavirus and sole member of the Rubivirus genus, is an 
enveloped single-stranded RNA virus with a single serotype.1,2 In an infected individual, the 
virus multiplies within the epithelial cells of the respiratory tract and then extends to the local 
lymph nodes through the blood stream. Secondary replication occurs and the virus then spreads 
to target organs.3 Generally a mild disease in children, rubella may be more severe in adults 
and can result in severe complications when pregnant women are infected. While more than 
50% of cases are asymptomatic, common symptoms include rash and low-grade fever plus any 
combination of nausea, malaise, mild conjunctivitis, upper respiratory infection, and 
lymphadenopathy.4–6 Infection during pregnancy may result in miscarriage, stillbirth, or a range 
of congenital abnormalities known as congenital rubella syndrome (CRS).7,8 Symptoms 
associated with CRS typically include cataracts, cardiac abnormalities, and sensorineural 
deafness, though many other defects may be observed as the RV can affect any organ.9,10 
Transmission of RV occurs through droplets from the respiratory tract, and infected individuals 
may be contagious from 7 days before to 7-12 days after rash onset.1 Humans are the only host 
for RV, and there are no known animal reservoirs. 
Worldwide, the number of reported rubella cases has decreased by 97% from 2000-
2016 as global coverage with rubella-containing vaccine (RCV) increased by 26% within this 
time period.11 The most commonly used licensed rubella vaccines are based on the live, 
attenuated RA 27/3 strain cultured in human diploid cells and can be administered as either a 
monovalent formulation or as a combination with other vaccine viruses, such as measles, 
mumps, and varicella.9,12 A single dose of the rubella vaccine induces high seroconversion rates 
(≥95%) and provides long-term immunity, similar to that produced by natural infection.12,13 In 
most countries, RCV is administered along with measles vaccine and thus follows the two-dose 
schedule for measles: the first dose at 9 months or 12-15 months and the second dose at 15-18 
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months or 4-6 years.14,15 By the end of 2016, 152 (78%) countries had introduced RCV into their 
national immunization schedules; however, due to differences in population sizes between 
countries, more than half of infants (53%) worldwide remain unvaccinated against rubella.11 In 
the Democratic Republic of Congo (DRC), rubella vaccine has yet to be introduced into the 
national immunization schedule, and the burden of rubella and CRS is likely to be high.  
Before introducing RCV into a country’s national immunization schedule, the World 
Health Organization (WHO) recommends that the country first achieve ≥80% coverage of the 
first dose of measles-containing vaccine (MCV1) through either routine immunization (RI) or 
vaccination campaigns. Previous mathematical models have suggested that an increase in CRS 
incidence may result from low coverage of RCV, due to the increase in the average age of 
infection.16,17 The occurrence of clusters of CRS cases in Costa Rica and Greece following a 
period of inadequate vaccine coverage has magnified this caution of RCV introduction.18,19 
However, this caution may result in a missed opportunity as rubella vaccine can be easily 
combined and administered with measles vaccine (MRCV). In South Africa, simulations of 
rubella vaccine introduction at the current estimates for measles vaccine coverage revealed 
that, due to a low basic reproduction number (R0) for rubella, the burden of CRS would be 
reduced despite vaccine coverage being below the recommended 80% threshold.20 Evidence 
from several countries has suggested that rubella may frequently have a low R0, indicating that 
disease incidence could be reduced at lower coverage.20–23 Based on these results, introduction 
of rubella vaccination in the DRC may reduce the burden of rubella and CRS even though the 
most recent Multiple Indicator Cluster Survey conducted revealed measles RI coverage to be 
much lower than the 80% threshold.24 
Despite the availability of an effective and affordable vaccine, rubella remains a leading 
cause of vaccine-preventable birth defects.11 Recently, the Global Alliance for Vaccines Initiative 
(GAVI) has opened a funding window for rubella vaccination.25 As the DRC already provides 
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two doses of measles vaccine through a combination of routine immunization and 
supplementary immunization activities (SIAs), introducing RCV as a combined measles-rubella 
vaccine may provide an opportunity for progressing towards rubella and CRS elimination. The 
DRC’s Expanded Program on Immunization (EPI) has committed to measles elimination by 
2020, and these efforts should be taken advantage of to progress towards the rubella 
elimination goals set by the Global Vaccine Action Plan 2011-2020 (GVAP).26,27 However, it is 
imperative to evaluate the impact of rubella vaccination prior to vaccine introduction due to the 
inverse relationship between RCV coverage rates and CRS incidence. Therefore, in 
collaboration with the Institute of Disease Modeling (IDM) and the 2013–2014 Demographic and 
Health Survey (DHS), we used an agent-based model to assess different vaccination scenarios 
in order to assess the impact of incorporating rubella vaccination into the national immunization 
schedule in the DRC.  
3.3 Methods 
Rubella transmission dynamics in the DRC were simulated using the Generic branch of 
Epidemiological MODeling software (EMOD), a stochastic agent-based model of disease 
transmission.28 A representative diagram of the health states and transitions included in the 
model can be seen in Figure 1. Using data from the most recent DHS conducted in the DRC in 
2013-2014 (EDS-RDC II),29 the model was calibrated to best match the reported age-of-
infection data specific to each province. Fixed input parameter values included known disease 
properties (e.g., infectious period), demographic variables (e.g., birth rate), and interventions 
(e.g., calendar of past SIAs). All simulations maintained a non-zero level of total infectiousness 
at all times, and persistent importation pressure ensured that re-introduction of disease was 
possible if local elimination were to occur.  
Simulations of the DRC population reflected age- and gender-based demography of 
each of the provinces and included all ages. All simulations had a time horizon of 30 years 
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representing the period from 2021-2050, and each year consisted of 365 discrete time steps. 
Birth, aging, and mortality occurred during each time step in the simulations. Birth rates and 
mortality probabilities for children under 5 years old were both age- and province-specific and 
were estimated from the EDS-RDC-II data29; mortality probabilities for individuals ≥ 5 years of 
age were adjusted to provide a national population structure similar to the DHS estimated 
population in 2013. These model parameters are summarized in Table 1. Simulations provided 
province-level resolution, and our primary outcomes for this analysis were the number of rubella 
and CRS cases. 
In order to estimate the infectivity of rubella within each province of the DRC, simulations 
were used to generate estimated age-stratified seronegativity profiles for each province. These 
profiles were then compared to the observed profiles obtained from serosurvey data collected 
as part the EDS-RDC-II in order to identify the R0 value with the highest likelihood. Rubella 
infections were characterized by incubation and infectious period distributions with mean 17 
days and 6 days respectively. All estimated R0 values by province are depicted in Figure 2. 
Individuals could only receive one infection and would receive life-long immunity following 
infection. Each infectious individual was randomly assigned an infectivity from a distribution with 
a mean equal to the base infectivity for their province. Rubella infections for each province were 
independent of each other, and the total infectivity of each province determined the total number 
of infections occurring during each subsequent time step. The total number of CRS cases was 
calculated post hoc using fixed probabilities for each age group. 
We modeled different vaccination scenarios for RCV introduction in the DRC as a 
combined measles-rubella vaccine. Immunity to rubella was assumed to be binary, and both 
naturally-derived immunity and vaccine-conferred immunity were assumed to provide life-long 
protection. Individuals could also receive maternal immunity, which provided an average of 3 
months protection; if an individual had maternal protection and received immunization, life-long 
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immunity was not conferred. All vaccination simulations began with an SIA catch-up campaign 
(targeting individuals between 9 months to 15 years of age) in 2020 and follow-up SIAs 
(targeting children between 9 months to 5 years of age) occurred every 4 years subsequently. 
To assess the impact of vaccination on rubella and CRS burden, we modeled two scenarios of 
nationwide RCV introduction with the first dose administered through RI at the current reported 
province-level MCV1 coverage rates and the second dose administered through SIAs with 
varying coverage rates of 70% and 50%. For baseline comparison, we modeled the incidence of 
rubella and CRS under the current situation of no RCV implementation. 
3.4 Results 
 Without the introduction of rubella vaccination, our model estimated the total number of 
rubella and CRS cases in the DRC over 30 years to be 151,021,183 and 147,543 respectively 
(Fig. 3). The provinces with the greatest burden of rubella were Nord-Kivu, Sud-Kivu, Haut-
Katanga, and Kinshasa, with each province modeled to have over 10 million cases of rubella 
infection. The provinces with the lowest estimated rubella burden were Bas-Uele and Haut-Uele. 
For CRS, Kasai and Tanganyika had the highest overall burden, each estimated to observe 
over 10,000 cases, while Mai-Ndombe had the lowest overall burden with under 1,000 cases. 
The predicted incidence of rubella per 100,000 was highest in Haut-Katanga and Lualaba and 
lowest in Haut-Uele and Maniema. The estimated incidence of CRS per million population was 
highest in Tanganyika and Haut-Uele and lowest in Haut Katanga and Mai-Ndombe for the 
baseline scenario. 
With nationwide RCV introduction at province-specific RI rates and 50% SIA coverage, 
the model estimated disease burden to reduce to 8,126,323 rubella cases and 27,070 CRS 
cases (Fig. 3). The provinces with the highest predicted rubella burden, as well as the highest 
incidence of rubella infection, were Tshuapa and Mai-Ndombe, each with over 800,000 cases. 
The provinces with the lowest estimated burden and incidence of rubella were Sud-Kivu and 
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Nord-Kivu with 4,861 and 5,505 cases respectively. CRS cases were estimated to be highest in 
Haut-Katanga with approximately 3,000 cases, while six provinces (Sud-Kivu, Nord-Kivu, 
Kinshasa, Haut-Uele, Kasai-Central, and Ituri) were modeled to observe less than 100 cases 
over the 30-year time period. The incidence of CRS for the 50% SIA coverage scenario was 
estimated to be highest in Maniema and Lualaba and lowest in Nord-Kivu and Sud-Kivu. 
When SIA coverage was increased to 70%, the number of rubella and CRS cases 
decreased to 1,477,302 and 2,859 respectively (Fig. 3). Similar to the 50% SIA coverage 
vaccination scenario, the provinces with the highest estimated burden and incidence of rubella 
infection were Mai-Ndombe and Tshuapa with over 300,000 cases in each province. 
Correspondingly, Mai-Ndombe and Tshuapa were also predicted to have the highest burden 
and incidence of CRS with 586 and 538 cases respectively. Meanwhile, Kasai-Central observed 
the lowest estimated burden and incidence of both rubella infection and CRS with 856 cases of 
rubella and 3 cases of CRS over the 30-year time period. A comparison of rubella and CRS 
burden by province and vaccination scenario is portrayed in Figure 4. 
3.5 Discussion 
With GAVI providing increased support and funding, countries may be considering 
introducing rubella vaccination into their national immunization schedules. Previously, countries 
have withheld RCV introduction due to the potential for a paradoxical increase in CRS 
incidence17; however, this endeavor may provide an opportunity to reduce rubella and CRS 
burden and may also strengthen existing measles immunization efforts.30 Prior to the vaccine 
introduction, countries must have an understanding of the current epidemiology of rubella and 
CRS and should potential areas of increased disease burden due to lower than recommended 
levels of vaccination coverage in order to evaluate the effectiveness of RCV introduction and the 
potential for rubella elimination. 
35 
Consistent with previous studies on RCV introduction, our data suggests that the 
addition of rubella vaccination can result in important public health benefits in reducing rubella-
related diseases. Additionally, our results indicate that even with RI coverage rates lower than 
the recommended 80%, introducing rubella vaccination into the national immunization schedule 
of the DRC has the potential to significantly reduce rubella and CRS burden within the country 
when it is supplemented with SIAs at coverage rates as low as 50%. As routine immunization 
remains sub-optimal and estimated coverage rates are low,24,31 these results are likely due to 
the low R0 values of rubella across provinces in the DRC.  
One of the primary concerns of introducing rubella vaccination is the potential increase 
in CRS burden. A review of the literature suggests that an increase in CRS burden due to low 
vaccine coverage may not be imminent and that the likelihood of this paradoxical effect is 
heavily dependent on the R0 value of rubella.32,33 In areas where the R0 of rubella is assumed to 
be 5-7, while short-term increases in CRS may occur, introduction of rubella immunization has 
been estimated to result in long-term decreases in CRS burden.33 The median R0 value of 
rubella across the African region has been estimated to be 5.2, with most African countries 
expected to have an R0 between 4-7.34 In the DRC, we estimated the R0 of rubella to be <7 in all 
provinces except for Mai-Ndombe (R0=8). Both of the vaccination scenarios modeled here are 
estimated to result in significant decreases in rubella and CRS burden. Introducing RCV at the 
reported province-level RI coverage rates supplemented by 50% coverage SIAs would prevent 
142,885,860 rubella cases and 120,473 CRS cases. Increasing SIA coverage to 70% would 
prevent an additional 6,649,021 rubella cases and 24,211 CRS cases. 
Our assumption of 70% SIA coverage may be an overestimation. However, notable 
decreases in rubella and CRS burden were still observed when SIA coverage was dropped to 
50%. Additionally, we assumed follow-up SIAs to occur every 4 years, which represents a 
conservative estimation as the WHO recommends SIAs to be implemented every 3 years in 
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countries with weak routine immunization systems in order to ensure high coverage and to 
control measles transmission.35 This strategy is recommended to continue until ≥80% RI 
coverage is achieved.36,37 Our agent-based simulation analyses broadly support introduction of 
rubella vaccination into the national immunization schedule of the DRC, particularly when 
bolstered by adequate SIA efforts. 
 Our analyses are subject to a number of limitations. First, the SIA coverage we included 
in our model may not represent true coverage rates. However, our assumptions of 50% and 
70% are likely conservative estimates as SIA coverage data has been reported to achieve 
≥90% and even exceed 100%. Second, disease transmission and vaccination within provinces 
were modeled to be independent of each other. We were unable to model migration between 
provinces, which could lead to increased rubella transmission among susceptible populations. 
Instead, we included a non-zero infectivity to all provinces to represent the risk of imported 
infections. This ensured that the probability of infection would remain non-zero in the event that 
local elimination would occur (i.e. zero infectivity from infected individuals). Finally, we could not 
model the probability of an individual receiving a second vaccine dose given that they received 
the first as this dependence of MRCV1 and MRCV2 is unknown.  
 Our analysis provides broad optimism that introduction of rubella vaccination into the 
DRC’s national immunization schedule will result in decreases in rubella and CRS burden, 
provided SIA coverage rates are adequately high. As our results highlight the importance of 
vaccination campaigns to prevent short- and long-term increases in CRS incidence, evaluation 
of the costs associated with vaccine introduction must be considered. Moving forward, 
strengthening of routine immunization programs to reduce the dependence on supplementary 
vaccination campaigns would be beneficial. If RI coverage can achieve and maintain high rates, 
there is high potential for the elimination of rubella in the DRC.
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3.6 Tables and figures 
Table 3.1. Parameters included in disease model 
Province 
Estimated 2019 
population* 
Birth rate  
(per 100,000)† 
Mortality† RI 
coverage‡ 
Vaccine 
efficacy¥ 0-29 days 30-359 days 360-1829 days 1830-34679 days ≥34680 days 
Bas-Uele 1,177,029 39.7 1.12E-03 1.11E-04 3.20E-05 
2.35E-05 1.0 
0.437 
97% 
Equateur 2,247,840 45.8 9.79E-04 1.14E-04 5.08E-05 0.519 
Haut-Katanga 5,440,816 49.0 1.23E-03 1.17E-04 3.70E-05 0.655 
Haut-Lomami 3,632,535 49.0 1.23E-03 1.17E-04 3.70E-05 0.542 
Haut-Uele 1,701,503 39.7 1.12E-03 1.11E-04 3.20E-05 0.600 
Ituri 5,226,511 39.7 1.12E-03 1.11E-04 3.20E-05 0.689 
Kasai 4,099,745 53.0 8.02E-04 1.52E-04 4.79E-05 0.298 
Kasai-Central 4,369,364 53.0 8.02E-04 1.52E-04 4.79E-05 0.753 
Kasai-Oriental 4,882,512 46.5 1.05E-03 1.02E-04 4.43E-05 0.420 
Kinshasa 8,647,308 36.1 5.56E-04 1.05E-04 2.49E-05 0.759 
Kongo Central 3,635,569 43.6 1.62E-03 1.08E-04 3.27E-05 0.686 
Kwango 2,294,566 42.4 9.08E-04 9.54E-05 2.35E-05 0.478 
Kwilu 4,592,343 42.4 9.08E-04 9.54E-05 2.35E-05 0.544 
Lomami 3,600,553 46.5 1.05E-03 1.02E-04 4.43E-05 0.422 
Lualaba 2,090,404 49.0 1.23E-03 1.17E-04 3.70E-05 0.422 
Mai-Ndombe 1,762,664 42.4 9.08E-04 9.54E-05 2.35E-05 0.377 
Maniema 2,391,851 39.1 1.12E-03 9.23E-05 3.20E-05 0.221 
Mongala 2,314,755 45.8 9.79E-04 1.14E-04 5.08E-05 0.319 
Nord Kivu 8,783,179 40.9 8.73E-04 4.89E-05 1.72E-05 0.801 
Nord-Ubangi 1,452,136 45.8 9.79E-04 1.14E-04 5.08E-05 0.389 
Sankuru 1,846,756 46.5 1.05E-03 1.02E-04 4.43E-05 0.389 
South Kivu 6,445,549 48.8 1.66E-03 1.43E-04 3.56E-05 0.733 
Sud-Ubangi 2,636,370 45.8 9.79E-04 1.14E-04 5.08E-05 0.431 
Tanganyika 2,815,857 49.0 1.23E-03 1.17E-04 3.70E-05 0.358 
Tshopo 2,965,751 39.7 1.12E-03 1.11E-04 3.20E-05 0.298 
Tshuapa 1,945,663 45.8 9.79E-04 1.14E-04 5.08E-05 0.349 
*UN OCHA Country Office in Democratic Republic of Congo. DR Congo - Health Zones 
†Demographic and Health Surveys (DHS). Deuxième Enquête Démographique et de Santé (EDS-RDC II 2013-2014). Rockville, MD 
‡National Institute of Statistics and United Nations Children’s Fund. Multiple Indicator Cluster Survey in the DRC, 2018.; 2018. 
¥Center for Disease Control and Prevention: Measles, Mumps, and Rubella (MMR) Vaccination: What Everyone Should Know 
[https://www.cdc.gov/vaccines/vpd/mmr/public/index.html] 
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Figure 3.1. Compartmental model of health conditions and transitions included in the disease 
model. There is no direct transition from maternally protected or exposed to immune 
(vaccination under these states is assumed to not confer immunity). Mortality is possible for all 
conditions and is unrelated to disease. 
 
Figure 3.2. Scatter plot of R0 values by province with mean and interquartile range. 
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Figure 3.3. Estimated total number of rubella and congenital rubella cases from 2021-2050 
stratified by vaccination scenario. 
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Figure 3.4. Maps of a) rubella and b) CRS incidence in the Democratic Republic of Congo by 
province and vaccination scenario. 
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Chapter 4: A Cost-Effectiveness Analysis of Rubella Vaccination Strategies for Children 
in the Democratic Republic of Congo 
4.1 Abstract 
Background: One of the goals of both the Global Measles and Rubella Strategic Plan and the 
Global Vaccine Action Plan is to achieve rubella elimination worldwide, with high rubella 
vaccination coverage as one of its main milestones. Only one dose of rubella vaccine is 
required to achieve high levels of immunity, and countries may combine measles and rubella 
vaccination to achieve more robust immunity. In the Democratic Republic of Congo, while poor 
health infrastructure has limited routine immunization (RI) efficiency, the use of supplementary 
immunization activities (SIAs) may provide an opportunity to reduce the burden of rubella and 
congenital rubella syndrome by incorporating rubella vaccination into the national immunization 
schedule. 
Methods: We estimated the cost-effectiveness of three vaccination scenarios by comparing 
incremental net costs per disability-adjusted life-year averted. Data specific to the Democratic 
Republic of Congo was used, and rubella vaccination coverage was assumed to equal province-
level measles vaccination coverage. When not available, values extracted from other low-
income countries were used. Inputs included the probabilities and costs of health outcomes 
caused by rubella infection or vaccination, treatment costs, vaccination costs, surveillance 
costs, and programmatic costs. 
Results: Compared to scenario 1 (no rubella immunization), scenario 2 (RCV1 by RI, RCV2 by 
50% SIA) would cost an additional $524 million and reduce total disability-adjusted life-years 
(DALYs) by 2.95 million. Compared to scenario 1, scenario 3 (RCV1 by RI, RCV2 by 70% SIA) 
would reduce total DALYs by 3.52 million and cost an additional $313 million. 
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Conclusions: Including rubella vaccination into the national immunization schedule of the 
Democratic Republic of Congo substantially reduced disease burden and was highly cost-
effective for both vaccine scenarios. While our results support investment in the introduction of 
rubella vaccination, decision-makers must consider all relevant data in a country-specific 
context to ensure optimal benefits. 
4.2 Introduction 
 Since the availability of rubella-containing vaccines (RCV) in 1969, global incidence of 
rubella has decreased significantly.1,2 From 2000 to 2016, the number of countries administering 
RCV as part of their national immunization schedule increased by 54% (from 99 to 152 
countries), and during this time period, the number of reported rubella cases decreased by 97% 
from 670,894 cases in 102 countries to 22,361 cases in 165 countries.2 Typically, rubella is a 
mild disease in children and manifests with a rash and low-grade fever along with any 
combination of nausea, malaise, mild conjunctivitis, upper respiratory infection, and 
lymphadenopathy.3–5 In adults, rubella infection may be more severe and include symptoms 
such as joint pain and encephalitis; however, the primary concern of rubella is when a pregnant 
woman becomes infected.6–8 When this occurs, the rubella virus can cross the placental barrier 
and infect fetal tissue, potentially resulting in either fetal death or a constellation of 
abnormalities, commonly including congenital heart defects, deafness, cataracts, and mental 
retardation, known as congenital rubella syndrome (CRS).9,10 Among pregnant women infected 
with rubella during the first trimester, up to 90% of liveborn infants may present with CRS, and 
the risk decreases with gestational age.11  
 In most countries where RCV is available, it is administered in conjunction with either 
measles (MR) or measles and mumps (MMR), and typically follows the two-dose schedule for 
measles: the first dose at 9 months or 12-15 months and the second dose at 15-18 months or 4-
6 years.12,13 While a single dose of RCV is sufficient enough to provide long-term immunity with 
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a high seroconversion rate of ≥95%, a second dose could be beneficial in capturing those who 
were either not vaccinated or who received the first dose, but did not seroconvert.1,14 Although 
less than a quarter of countries have yet to introduce RCVs, due to differences in population 
sizes between countries, more than half of infants (53%) worldwide remain unvaccinated 
against rubella.2 In the Democratic Republic of Congo (DRC), rubella vaccine has yet to be 
introduced into the national immunization schedule, and the burden of rubella and CRS is likely 
to be high. Despite limitations in documentation, recent studies have estimated that ~3,000 
infants are born with CRS annually in the DRC and that approximately one-third of children 6- to 
59-months are rubella antibody seropositive.15,16 
 The primary goal of rubella immunization is to prevent congenital rubella, and there are 
two general approaches of using RCVs: focus solely on reducing CRS by immunizing only 
adolescent girls and women of childbearing age or focus on interrupting transmission of rubella 
virus by immunizing all children through routine immunization (RI). Research in the US, Israel, 
Japan, Iceland, and Norway has evaluated the economic impact of rubella-associated 
morbidities and the cost-effectiveness of rubella vaccination in these populations.17–22 It has 
been documented by Gudnadóttir and by Golden and colleagues that vaccination targeting 
specifically susceptible adolescent girls and women may be a more cost-effective strategy 
compared to vaccination of all children19,21; however, with this approach, the epidemiology and 
circulation of rubella would likely remain unaffected as most infections occur before the age of 
immunization.1 Additionally, elimination of CRS would not likely be achieved through this 
strategy as it would require every susceptible woman to be vaccinated.1  
Another consideration prior to introducing RCV is the suggested inverse relationship 
between RCV coverage and CRS incidence. Previous mathematical models have suggested 
that an increase in CRS incidence may result from low coverage of RCV, due to the increase in 
the average age of infection.23,24 The World Health Organization (WHO) recommends that a 
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country first achieve ≥80% coverage of the first dose of measles-containing vaccine (MCV1), 
through either RI or vaccination campaigns, before incorporating RCV into the national 
immunization schedule. This caution has been amplified following instances where a rise in 
CRS cases have occurred following a period of low vaccination coverage, such as in Costa Rica 
and Greece.25,26 However, simulations in South Africa have suggested that in areas where the 
basic reproduction number (R0) for rubella is low, CRS incidence could be reduced even when 
vaccine coverage falls below the recommended level.27 Based on these findings, incorporating 
rubella vaccination into the national immunization schedule of the DRC may provide an 
opportunity to reduce the burden of rubella and CRS. 
 While the DRC does not currently provide RCV, it does provide two doses of measles 
vaccination through a combination of RI and supplementary immunization activities (SIAs). 
Although the health infrastructure in the DRC has struggled with limited roads and access to 
electricity and water, slight improvements in vaccine coverage have been realized. Based on 
WHO/UNICEF estimates, national MCV1 coverage in the DRC have been steadily increasing 
from 72% in 2009 to 80% in 201728; however, based on estimates from the most recent Multiple 
Indicator Cluster Survey conducted in the DRC, measles RI coverage was much lower than the 
recommended 80% threshold.29 As rubella and measles immunization can be easily combined, 
there may be opportunity to leverage ongoing measles elimination activities to support rubella 
elimination. Comparing the costs and benefits of introducing rubella vaccination as a combined 
MR vaccine may provide insight in selecting the most optimal strategy for rubella immunization 
in the DRC.  
 Data on the public health and economic consequences of RCV introduction in the DRC 
will play an important role in guiding future policy decisions, vaccine delivery strategies, and 
other prevention and control efforts for rubella-related disease. While several studies have 
evaluated the cost-effectiveness of rubella and CRS elimination, few have considered varying 
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vaccination strategies. Differences in public health infrastructure and rubella epidemiology 
between regions requires analyses to be country-specific. Therefore, the aim of this analysis 
was to assess the health and economic impacts in DRC of implementing rubella immunization 
under different vaccination scenarios compared to the current no-vaccination scenario. 
4.3 Methods 
 We developed a cost-effectiveness model to compare varying scenarios for rubella 
vaccine introduction in the DRC. The primary outcome measure is the incremental net cost per 
disability-adjusted life-year (DALY) averted. DALYs combine years of life lost due to premature 
death (YLLs), calculated from the average life expectancy at the age and year of rubella/CRS 
mortality, and life-years lost due to disease morbidity (YLDs), calculated using the duration of 
rubella/CRS by standard DALY weights. DALY weights indicate the proportion of healthy time 
lost due to living with rubella infection/CRS. Health outcomes include vaccine-related 
complications, rubella infection, and CRS.  
 We used an ingredients-based approach to estimate vaccination-related costs by 
assigning a value to each dose of MR vaccine administered through either routine services or 
an SIA. Costs associated with RI included personnel, injection equipment (auto-disable syringes 
and safety boxes), cold chain costs (vaccine carriers, cold boxes, ice packs, refrigerator parts, 
and fuel), and transportation. Additional costs were incorporated into the model for vaccines 
administered through SIAs, including social mobilization, supervision, and planning/training, as 
well as higher costs for cold chain, transportation, and personnel in order to account for difficult-
to-reach populations. The wastage factor indicates the fraction of vaccines not used, and 
wastage factors for SIAs are generally smaller than for RI. In the DRC, the wastage factor was 
estimated at 3.42 for RI and 1.15 for SIAs.30–33 The Centers for Disease Control and Prevention 
(CDC) estimates one dose of RCV to be 97% effective, thus a small proportion of individuals will 
always remain susceptible even after vaccination.34 We also included global level costs 
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associated with vaccine stockpile and recommended surveillance for rubella and CRS. All 
immunization-associated costs and inputs are summarized in Table 1. 
Health outcome probabilities and costs associated with rubella and CRS, as well as 
vaccine-related complications, were obtained through literature review. Costs associated with 
rubella infection and vaccine-related adverse events varied by gender and age and were 
calculated with costs associated with home care. Health outcomes were measured in DALYs 
and were gender- and age-specific. On average, adult women were more likely to experience 
adverse events, related to both rubella infection and vaccination, and thus had greater DALYs. 
Health outcome costs and DALYs can be seen in Table 2. Specific health outcomes include 
anaphylaxis, febrile seizures/convulsions, thrombocytopenia, arthropathy, cardiac defects, eye 
abnormalities, auditory defects, and intellectual disability. Probabilities for these outcomes 
varied by gender and age and are summarized in Table 3. 
The vaccination scenarios we assessed included: 1) No RCV introduction (baseline 
comparison), 2) RCV introduction nationwide with the first dose through RI at the current 
reported province-level MCV1 coverage rates and the second dose through SIAs at 50% 
coverage, 3) RCV introduction nationwide with the first dose through RI at the current reported 
province-level MCV1 coverage rates and the second dose through SIAs at 70% coverage. All 
costs and health outcomes were modeled over a time horizon of 30 years and were discounted 
at a rate of 3%. 
4.4 Results 
 Compared to scenario 1, scenarios 2 and 3 were more effective regarding health 
outcomes, with scenario 3 being the most effective, however, scenario 1 was the least 
expensive option (Fig. 1). Over 30 years, without the introduction of rubella immunization, there 
would be 151,021,183 cases of rubella and 147,543 cases of CRS, and the costs associated 
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with rubella infection were estimated to total $1.8 billion. Regarding specific health outcomes, 
this scenario would lead to 3,243 cases of encephalitis, 8,330 cases of thrombocytopenia, and 
2,979,048 cases of transient arthropathy, resulting in 3,595,394 DALYs (Table 4). 
Introducing two doses of rubella vaccination at province-specific RI coverage rates and 
50% SIA coverage (scenario 2) would cost an additional $524.5 million, but would prevent 
142,894,860 cases of rubella and 120,473 cases of CRS (Table 4b). While vaccination costs 
would total $2 billion, disease costs would be reduced by $1.5 billion. Health outcomes 
associated with vaccination would result in 2,305 cases of anaphylaxis, 230,452 febrile 
seizures/convulsions, and 230 cases of thrombocytopenia. Health outcomes associated with 
rubella infection would total 163 encephalitis cases, 425 thrombocytopenia cases, and 228,592 
transient arthropathy cases (Table 4a). Compared to scenario 1, scenario 2 would reduce 
DALYs to 643,004 (a reduction of 2,952,390 DALYs) and the incremental cost-effectiveness 
ratio (ICER), defined as the cost per DALY averted, for scenario 2 compared to scenario 1 
would be 177.64 (Table 4b). 
When SIA coverage was increased to 70% (scenario 3), the increase in total costs was 
reduced to $312.9 million when compared to no rubella vaccination. Vaccination and disease 
costs would total $2.1 billion and $29.6 million respectively, a decrease of $1.7 billion relative to 
scenario 1 (Table 4b). Vaccine-related adverse events would include 2,773 anaphylaxis cases, 
277,288 febrile seizures/convulsions, and 277 thrombocytopenia cases, while adverse events 
associated with rubella infection would include 30 cases of encephalitis, 76 cases of 
thrombocytopenia, and 26,717 cases of transient arthropathy (Table 4a). Compared to scenario 
1, scenario 3 would reduce the total number of DALYs by 3.5 million, resulting in 71,901 DALYs, 
and the ICER comparing scenario 3 to 1 would equal 88.82 (Table 4b). Therefore, none of the 
scenarios dominated over the rest as scenario 1 required the lowest total costs, but scenario 3 
yielded the fewest number of rubella and CRS cases. 
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4.5 Discussion 
 Introducing RCV in the DRC through routine immunization and supplementary 
immunization activities is projected to reduce rubella-associated morbidity, compared to no 
vaccination, with increased expenditures. Our results demonstrate that administering rubella 
vaccination as a combined MR vaccine would be highly cost-effective, even at the current 
province-level RI rates with SIA coverage rates as low as 50%.  
 The WHO recommends rubella vaccination as a safe and effective measure to reduce 
the burden of congenital rubella infections, including CRS. Additionally, WHO recommends that 
countries already providing 2 doses of measles vaccine, through either RI, SIAs, or both, should 
consider including RCVs in their immunization programs and suggests that countries should 
take advantage of accelerated measles control and elimination activities in order to do so.1 Past 
studies have proven rubella vaccination to be cost-effective and economically justified, however, 
these studies have focused on high- and middle-income countries where coverage is >80%.35–37 
Few studies have examined the cost-effectiveness of rubella vaccination at sub-optimal levels of 
coverage in low-income countries in Africa. Our simulations indicate that administering RCVs at 
the current reported province-level coverage rates would result in a decrease in the number of 
DALYs associated with rubella infection when complemented with SIA services.  
 In terms of projected advantages, scenario 2 would cost an additional $524.5 million, but 
would prevent 2,952,390 DALYs when compared to scenario 1. Scenario 3 would prevent an 
additional 571,103 DALYs and would cost $211.5 million less than scenario 2. Compared to 
scenario 1, both scenarios 2 and 3 would save over $1 billion in disease-related costs and the 
majority of costs resulted from programmatic costs related to vaccine stockpile and 
management and to establishing and maintaining rubella and CRS surveillance systems.  
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 The WHO’s Choosing Interventions that are Cost-Effective (WHO-CHOICE) project 
defines a highly cost-effective intervention as one that costs less than the national annual gross 
domestic product (GDP) per capita per DALY averted; a cost-effective intervention would cost 
less than three times the national annual GDP per capita per DALY averted.38–41 The nominal 
GDP per capita for the DRC is estimated to be ~$500.42–44 The ICERs resulting from our 
analyses suggest that introducing rubella vaccination in the DRC would be highly cost-effective 
for both scenario 2 ($177.64/DALY averted) and scenario 3 ($88.82/DALY averted). As there 
have been documented limitations on the use of cost-effectiveness thresholds,45,46 decision-
makers should consider these results alongside all relevant country-specific data, such as 
affordability, budget impact, feasibility, and any other criteria deemed important in the local 
context, in order to ensure optimal health outcomes and the best use of expenditures.  
 While our analyses conclude that RCV introduction would be highly cost-effective, some 
limitations to our study exist. We included costs estimated based on available evidence from 
other low-income countries as accurate data on non-vaccine and programmatic costs specific to 
the DRC were not available. However, some of the global level costs may be overestimated as 
these costs were estimated for all countries regardless of income classification. Our analyses 
did not account for all of the possible factors that may impact the costs and health outcomes of 
vaccination efforts. For example, while we incorporated transportation costs as part of non-
vaccine costs, there may be increased costs associated with traveling across different terrains 
or traveling to more remote areas. Additionally, variables that would be difficult to quantify and 
that could not be included in our model may exist. For example, the efforts of introducing a new 
vaccine and conducting additional vaccination campaigns may divert time and resources from 
other health initiatives which could lead to inaccurate costs. Disease costs and probabilities 
were also obtained from proxy countries, but there is likely heterogeneity across provinces in 
the DRC that could not be accounted for in our model. While these costs may not represent all 
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of the costs associated with rubella complications, they do attempt to account for costs 
associated with loss of productivity and receiving home care. Lastly, the ICERs calculated here 
are point estimates and are likely to have uncertainty in both the measure of cost and the 
measure of effectiveness. Future studies may consider conducting bootstrap analyses in order 
to approximate confidence intervals to address these uncertainties. 
 In general, introducing rubella vaccine as a combined MR vaccine appears to be a cost-
effective scenario in the DRC, provided that SIA rates reach at least 50% coverage. While our 
results suggest that disease burden may be reduced by administering RCV at the current 
province-level RI coverage rates, targeted efforts to achieve and maintain high RI rates should 
be prioritized. Decision-makers need to consider practical limitations and all relevant data and 
estimates in a context-specific process in order to ensure improved health outcomes while 
optimizing good value for money.    
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4.6 Tables and figures 
Table 4.1. Variables associated with immunization activities with sources. 
Variable   Value   Source 
Routine Immunization (per dose)     
Vaccine w/freight     
MCV  $0.318  [1] 
MRCV  $0.656  [2] 
Non-vaccine Cost (injection equipment use and 
disposal, cold chain, personnel, training, and other 
misc. costs)   
$0.350  [3,4,5] 
Total RI costs per dose (MCV)  $0.668   
Total RI costs per dose (MRCV)  $1.006   
     
Supplementary Immunization Activities (per dose)     
Vaccine w/freight     
MCV  $0.318  [1] 
MRCV  $0.656  [2] 
Non-vaccine Cost (addition of social mobilization, 
supervision, planning/training, administrative costs, and 
transportation costs)   $0.810  
[5,6] 
Total SIA costs per dose (MCV)  $1.128   
Total SIA costs per dose (MRCV)  $1.466   
     
Global Level Costs     
Cost to create a global rotating MR vaccine stockpile 
(one-time cost)  $50,000,000  
[5] 
Annual surveillance costs, including expanded rubella 
and CRS surveillance, pre-eradication  $60,000,000  
[5] 
Annual technical support, operational research, 
stockpile management, communication, and 
coordination costs, pre-eradication  $35,000,000  
[5] 
     
Wastage factor     
RI  3.42  [3,4] 
SIAs  1.15  [4,7,8] 
Discount rate   0.03   Assumption 
1. Vaccine Price Data - Measles [https://www.unicef.org/supply/files/2018_04_04_Measles.pdf]. 
2. Vaccine Price Data - Measles-Rubella [https://www.unicef.org/supply/files/2018_04_17_MR.pdf]. 
3. Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy TV, Cortese M, Rodewald L. 
Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics, 2014; 
133(4):577–585. 
4. Dayan GH, Cairns L, Sangrujee N, Mtonga A, Nguyen V, Strebel P. Cost-effectiveness of three different vaccination 
strategies against measles in Zambian. 
5. Thompson KM, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management 
policies Risk Anal. 2016; 36:1357-82. 
6. Gandhi G, Lydon P. Updating the evidence base on the operational costs of supplementary immunization activities for 
current and future accelerated disease control, elimination and eradication efforts. BMC Public Health, 2014; 14:16. 
7. Programme Enlargi de Vaccination: Measles Vaccination Budget: 2013. In.; 2013. 
8. Vaccination PEd: RDC Synthese du Budget Campagne de Suivi 2013: Bandundu, Equateur, Kinshasa, Orientale. In.; 
2013. 
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Table 4.2. Health outcome costs and DALY estimates by gender associated with vaccination 
and rubella infection. 
Vaccine or Virus   Costs* Source 
Vaccine adverse events (per dose)    
[1] 
0 to 14 years  $0.003 
Females, ≥15 years  $0.100 
Males, ≥15 years  $0.003 
Rubella infection    
Females, 0 to 14 years  $5 
Females, ≥15 years  $46 
Males, 0 to 14 years  $5.49 
Males, ≥15 years  $9.54 
CRS (per case)  $11,266 
    
  DALYs 
    Male Female 
MRCV    
<5 years  0.00002 0.00002 
5 to 14 years   0.00002 0.00002 
15 to 44 years  0.00001 0.0035 
45+ years  0.00001 0.000115 
Rubella infection    
<5 years  0.0003 0.0003 
5 to 14 years   0.0003 0.0003 
15 to 44 years  0.0195 0.195 
45+ years  0.006 0.055 
CRS   29 29 
1. Thompson KM, Odahowski CL. The Costs and Valuation of Health Impacts of Measles and Rubella 
Risk Management Policies. Risk Anal. 2016;36(7):1357-1382. doi:10.1111/risa.12459 
*Cost inputs account for treatment costs, productivity losses, and costs associated with home care. 
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Table 4.3. Health outcome probabilities by gender and age group. 
 Male Female 
Source Health Outcome <5 yr 5–14 yr  15–44 yr 45+ yr <5 yr 5–14 yr  15–44 yr 45+ yr 
Vaccine Adverse Events (per dose)         
[1] 
Anaphylaxis 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
Febrile seizures/convulsions 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Minor reactions 10 10 10 10 10 10 10 10 
Thrombocytopenia 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
Thrombocytopenia mortality 0.000003 0.000003 0.000003 0.000003 0.000003 0.000003 0.000003 0.000003 
Arthropathy, transient (excluding 
adult men) 
-- -- -- -- 0.01 0.01 0.1 0.1 
Arthropathy, chronic (≥15-year-old 
women) 
-- -- -- -- 0 0 0.01 0.01 
         
Rubella Adverse Events (per infection)         
Asymptomatic infection 49.9 49.9 49.0 49.0 49.9 49.9 39.6 39.6 
Encephalitis 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0.002 
Encephalitis mortality 0.00009 0.00009 0.00011 0.00011 0.00009 0.00009 0.00011 0.00011 
Thrombocytopenia 0.005 0.005 0.006 0.006 0.005 0.005 0.006 0.006 
Thrombocytopenia mortality 0.00014 0.00014 0.00018 0.00018 0.00014 0.00014 0.00018 0.00018 
Transient arthropathy 0.3 0.3 2 2 0.3 0.3 21 21 
Chronic arthropathy 0 0 0.4 0.4 0 0 4 4 
Uncomplicated illness 49.9 49.9 49.0 49.0 49.9 49.9 39.6 39.6 
1. Thompson KM, Odahowski CL. The Costs and Valuation of Health Impacts of Measles and Rubella Risk Management Policies. Risk Anal. 2016;36(7):1357-
1382. doi:10.1111/risa.12459 
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Table 4.4. Results of cost-effectiveness analysis comparing rubella vaccination scenarios 1-3 over 30 years, Democratic Republic of Congo. 
a. Summary of health outcomes by vaccination scenario. 
Health Outcome Baseline (no vaccine) Nationwide RCV (50% SIA) Nationwide RCV (70% SIA) 
Anaphylaxis 0 2,305 2,773 
Febrile 
seizures/convulsions 0 230,452 277,288 
Minor reactions 0 23,045,232 27,728,752 
Thrombocytopenia 8,330 655 353 
Thrombocytopenia 
mortality 
236 19 10 
Asymptomatic infection 79,665,984 3,952,929 726,031 
Encephalitis 3,243 163 30 
Encephalitis mortality 150 8 1 
Transient arthropathy 2,979,048 240,114 40,582 
Chronic arthropathy 489,618 40,113 4,377 
Uncomplicated illness 79,665,984 3,952,929 726,031 
          
b. Summary of the cost-effectiveness analysis comparing scenarios 2 and 3 to scenario 1. 
Vaccination 
Scenario 
Total Costs Over 30 Years (US$) Effectiveness 
ICER  
($ per DALY 
averted) 
  
Disease  
Costs 
Vaccination 
Costs* 
Total  
Costs 
Δ  
Cost 
Rubella 
Cases 
CRS 
Cases 
Total 
DALYs 
Δ DALYs 
(averted)   
1 $1,767,291,729 $0 $1,767,291,729 -- 151,021,183 147,543 3,595,394 -- -- 
2 $254,383,617 $2,037,364,310 $2,291,747,927 $524,456,198 8,126,323 27,070 643,004 2,952,390 177.64 
3 $29,574,806 $2,050,659,847 $2,080,234,654 $312,942,924 1,477,302 2,859 71,901 3,523,493 88.82 
1Scenario 1: No RCV introduction, Scenario 2: Nationwide RCV1 through RI, RCV2 through 50% SIA coverage, Scenario 3: Nationwide RCV1 through RI, RCV2 through 70% SIA 
coverage 
2All costs and DALYs were discounted at a rate of 3%. Costs were rounded to the nearest dollar. 
*Vaccination costs account for the difference in costs between MCV and MRCV. 
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Figure 4.1. Cost-effectiveness analysis for three scenarios of rubella immunization. 
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Chapter 5: Public health significance 
 While rubella no longer constitutes as serious a threat as it once did in several countries, 
it remains a danger for millions of mothers and children in low-income countries. Despite the 
progress that has been made towards rubella elimination and control, approximately 100,000 
babies are born with congenital rubella syndrome (CRS) annually worldwide,1 and the number 
of CRS cases remains especially high in countries without rubella immunization.2 In the 
Democratic Republic of Congo (DRC), rubella immunization has not been introduced into the 
country’s national vaccination program, although there were tentative plans to do so by 2020,3 
and the incidence of CRS has been estimated to be 69 per 100,000 live births, equating to 
approximately 3,000 infants.2 As rubella-containing vaccines (RCVs) are typically administered 
in conjunction with measles vaccination, it is highly recommended that countries take advantage 
of efforts towards measles control and elimination to introduce rubella immunization, and while 
RCVs have proven highly effective in reducing rubella-related disease burden, there has been 
concern around introducing the vaccine at low coverage rates. Estimates from the most recent  
Multiple Indicator Cluster Survey (MICS) indicate that measles vaccination coverage among 
provinces in the DRC are mostly below the 80% recommended level, with only one province 
surpassing this threshold at 80.1%.4 As the country may still be considering RCV introduction in 
the near future, this dissertation aims to fill in gaps in the current understanding of rubella 
epidemiology in the DRC and to evaluate the health and economic impact of introducing rubella 
vaccination at the current province-level coverage rates.  
In the first study of rubella seropositivity, rubella seroprevalence was found to be high 
among adults in the DRC and was associated with increasing age and province. Our findings 
highlight that there may be widespread circulation of the rubella virus throughout all provinces in 
the DRC and that although most viremia and antibody seroconversion occur before 15 years of 
age, over 10% of individuals remain susceptible to rubella infection at the beginning of 
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adulthood, including women entering reproductive age. This is concerning as up to 90% of 
fetuses can be affected by multiple defects among pregnant women infected with rubella.5 In 
order to reduce the risk of rubella-associated diseases, rubella vaccination must be introduced 
into the national immunization schedule and achieve high coverage, and any consideration to 
introduce rubella vaccination must account for the impact of vaccination at lower than 
recommended coverage levels, especially on the incidence of CRS, as well as the economic 
impact and costs associated with vaccine introduction.  
The last two studies focused on evaluating the change in rubella and CRS burden that 
would follow RCV introduction and on comparing the cost-effectiveness of various vaccination 
scenarios. Our results show that vaccine introduction in the DRC would result in significantly 
decreased rubella and CRS burden over a 30-year period, despite low rates of vaccine 
coverage. The probability of an increase in CRS cases following periods of low RCV coverage is 
likely to be heavily dependent on the reproductive number (R0) of rubella,6,7 and we estimated 
the R0 of rubella to be low enough (<7) throughout provinces in the DRC that this paradoxical 
effect would be avoided. In terms of costs and benefits, introducing rubella vaccine as a 
combined vaccine with measles immunization appears to be a cost-effective scenario in the 
DRC. Using the guidelines defined by the World Health Organization’s Choosing Interventions 
that are Cost-Effective project, RCV introduction would be considered highly cost-effective, 
compared to no vaccination, when current routine immunization levels are strengthened by 
supplementary immunization activities (SIAs) with at least 50% coverage. However, these 
results should be considered along with practical limitations and all relevant data in a context-
specific process to guarantee health benefits at optimal costs. While measles vaccine coverage 
has been lower than the recommended 80% in the DRC, our results broadly support investment 
in addition of rubella immunization.  
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As the Global Alliance for Vaccines Initiative has opened a funding window for rubella 
vaccination, there may be an opportunity to take advantage of measles eradication efforts in the 
DRC to progress towards rubella control and elimination. As the DRC has planned for RCV 
introduction in recent years, these findings may prove useful in future decisions in health policy. 
In the interim, the country should focus on establishing and strengthening rubella and CRS 
surveillance, to provide better estimates on disease burden, as well as on achieving and 
maintaining high levels of population immunity. More accurate estimates on vaccine coverage, 
especially SIA coverage, and on treatment costs would also help to inform future research. 
Once RCVs are successfully incorporated into the DRC’s national immunization schedule, 
further analyses on the impact of vaccination will be needed so that other countries that have 
yet to introduce RCVs may be better informed. Monitoring disease progress and improving the 
capacity to maintain nationally high vaccine coverage levels will be crucial next steps in 
advancing toward rubella and CRS elimination. 
 
 
 
 
 
 
 
 
 
66 
5.2 References 
1.  Initiative M& R. Measles and Rubella Move Fast Factsheet. 2017. 
2.  Alleman MM, Wannemuehler KA, Hao L, et al. Estimating the burden of rubella virus infection 
and congenital rubella syndrome through a rubella immunity assessment among pregnant 
women in the Democratic Republic of the Congo: Potential impact on vaccination policy. Vaccine. 
2016;34(51):6502-6511. doi:10.1016/j.vaccine.2016.10.059 
3.  Ministry of Public Health - Democratic Republic of the Congo. Plan Pluri Annuel Complet Du PEV 
de La République Démocratique Du Congo, 2015–2019. Kinshasa, République Démocratique du 
Congo; 2014. 
4.  National Institute of Statistics and United Nations Children’s Fund. Multiple Indicator Cluster 
Survey in the DRC, 2018.; 2018. 
5.  Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at 
successive stages of pregnancy. Lancet (London, England). 1982;2(8302):781-784. 
http://www.ncbi.nlm.nih.gov/pubmed/6126663. 
6.  Wesolowski A, Mensah K, Brook CE, et al. Introduction of rubella-containing-vaccine to 
Madagascar: implications for roll-out and local elimination. J R Soc Interface. 
2016;13(117):20151101. doi:10.1098/rsif.2015.1101 
7.  Winter AK, Pramanik S, Lessler J, Ferrari M, Grenfell BT, Metcalf CJE. Rubella vaccination in India: 
Identifying broad consequences of vaccine introduction and key knowledge gaps. Epidemiol 
Infect. 2018;146(1):65-77. doi:10.1017/S0950268817002527 
 
 
